In addition, it has been reported that the effects of ERα antagonists, including tamoxifen, a known risk factor for the development of EEC, are tissue-specific, differing between EEC and BC by inhibiting the growth of BC cells and stimulating the growth of EECs [22]. Here, ESR1 is linked to breast cancer.